Search results
13 mar 2018 · The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as well as in preventing Aβ production, aggregation, or downstream neurotoxic consequences, in part through the blockade of extrasynaptic NMDAR.
- Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
Although memantine is approved only for AD, two double-blind...
- Memantine for the Treatment of Dementia: A Review on its ... - PubMed
The data in preclinical studies suggests that MEM has a...
- Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
2 mar 2007 · Although memantine is approved only for AD, two double-blind studies have suggested possible beneficial effects of memantine in patients with vascular dementia (Orgogozo et al 2002; Wilcock et al 2002).
6 cze 2023 · Further pharmacological effects of memantine have been revealed and applied for clinical applications, such as neuroprotection in ischemic brain injury after cardiac arrest, treatment of vascular dementia, treatment of ischemic stroke, treatment of Parkinson's disease dementia, alleviation of acute lung injury (ALI), and so on.
The effect of memantine on vascular dementia of mild to moderate severity has been assessed in two large randomised, double-blind, placebo‐controlled studies , 15,16 in which a total of 900 participants fulfilling standardised diagnostic criteria were enrolled.
The data in preclinical studies suggests that MEM has a positive impact on improving AD brain neuropathology, as well as in preventing Aβ production, aggregation, or downstream neurotoxic consequences, in part through the blockade of extrasynaptic NMDAR.
5 lis 2022 · The N-methyl-D-Aspartate receptor antagonist memantine with its less popular monoamine reuptake-inhibiting properties provides beneficial effects in patients with advanced Alzheimer’s disease on an acetylcholine esterase inhibitor treatment regimen.
Memantine's side effects include fatigue, increases in blood pressure, dizziness, headache, constipation, confusion, and sleepiness, among others. Memantine is the only FDA-approved drug for the treatment of Alzheimer's disease that is not an acetyl cholinesterase inhibitor.
